Clinical Efficacy of Sorafenib Combined with Low Dose Cytarabine for Treating Patients with FLT3+ Relapsed and Refractory Acute Myeloid Leukemia.
- Author:
Xiao-Shu LIU
1
;
Hui LONG
1
;
Yu-Xian HUANG
1
;
Jian-Hui XU
1
;
Jun-Yu ZHU
1
;
Qing-Feng DU
1
;
Bing-Yi WU
2
Author Information
- Publication Type:Journal Article
- MeSH: Cytarabine; therapeutic use; Humans; Leukemia, Myeloid, Acute; drug therapy; Niacinamide; analogs & derivatives; therapeutic use; Phenylurea Compounds; therapeutic use; Recurrence; Remission Induction; Treatment Outcome; fms-Like Tyrosine Kinase 3; metabolism
- From: Journal of Experimental Hematology 2016;24(2):394-398
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the efficacy and safety of sorafenib combined with low dose cytarabine for treating patients with FLT3(+) relapsed and refractory acute myeloid leukemia (FLT3(+) RR-AML).
METHODSSeven patients with FLT3(+) RR-AML were treated with sorafenib and low dose cytarabine. The curative rate and adverse effects were observed in these patients.
RESULTSOut of 7 RR-AML patients after treatment, 5 patients achieved complete remission (CR), 2 patients achieved partial remission (PR), and the overall response rate (ORR) after one course of therapy was 100%. No severe bleeding, nausea, vomiting and other side effects were found in these patients.
CONCLUSIONSorafenib combined with low dose cytarabine can effectively induce the remission of FLT3(+) RR-AML patients, and is worth for further clinical trails to verify its safty and efficiency.
